Tech Company Financing Transactions
Wheeler Bio Funding Round
Wheeler Bio closed a Series A investment round on 10/4/2022. Investors included ATUM, Charles River Laboratories and Echo Investment Capital.
Transaction Overview
Company Name
Announced On
10/4/2022
Transaction Type
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
Wheeler will use the new funding to expand its state-of-the-art drug substance GMP manufacturing facility in the Ziggurat building in Oklahoma City.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
The Ziggurat 120 Robert South Kerr Avenue
Oklahoma City, , OK 73102
USA
Oklahoma City, , OK 73102
USA
Phone
Undisclosed
Website
Email Address
Overview
Wheeler Bio brings biologics drug innovators, discovery CROs, and CDMOs together to solve an outdated industry bottleneck with a unique partnering model, built on shared success and lasting collaborations. The typical momentum drop between discovery and development poses significant challenges for emerging biopharma companies adding technical, financial, and regulatory risks. We believe these lifecycle challenges can be reduced with more democratization of manufacturing platforms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jesse McCool
Chief Financial Officer
Matt Hamilton
Chief Operating Officer
Roger Lias
Chief Technical Officer
Stephen Hamilton
Co-Founder
Yuk Chun
Browse more venture capital transactions:
Prev: 10/4/2022: Eclypsium venture capital transaction
Next: 10/4/2022: Highnote venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs